The effect of pharmacoeconomics on company research and development decisions

PharmacoEconomics

Volumn 11, Issue 5, 1997, Pages 389-397

  Grabowski, Henry ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG TOLERANCE; PRIORITY JOURNAL;

EID: 0030909882     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711050-00002     Document Type: Article

References (31)

1. Kunze ZM, Lumley CE, Walker SR. Socioeconomic evaluation of medicines: a survey of the international pharmaceutical industry. Carshalton: Centre for Medicines Research, 1993
2. DiMasi J, Hansen R, Grabowski H, et al. The cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42
3. Pharmaceutical Manufacturers Association, PMA Annual Survey Report: Trends in U.S. Pharmaceutical Sales and R&D, Washington, DC, 1993
4. DiMasi J, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994; 55 (6): 609-22
5. U.S. Congress Office of Technology Assessment. Pharmaceutical R&D: costs, risks and rewards. Washington, DC: Government Printing Office, 1993
6. The Boston Consulting Group. The changing environment for U.S. pharmaceuticals. New York: Apr 1993
7. Grabowski H, Vernon J. Returns to R&D on new drug introductions in the 1980s. J Health Econ 1994; 13: 383-406
8. Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R&D. Manage Sci 1990; 36 (7): 167-85
9. Shaw HK. Catalysts for change: the impact of generic drugs on the pharmaceutical industry. Burlington (MA): Spectrum, Report 38. Decision Resources, Dec 28, 1992
10. Grabowski H, Vernon J. Longer patents for increased generic competition in the US: the Waxman-Hatch Act after one decade. Pharmacoeconomics 1996; 10 Suppl. 2: 110-23
11. Sloan F, Grabowski H, editors. The role of cost-effectiveness analysis in public and private sector decisions. Soc Sci Med 1997. In press
12. Davies L, Coyle D, Drummond M, et al. Current status of economic appraisal of health technology in the European Community: report of the network. Soc Sci Med 1994; 38 (12): 1601-7
13. Drummond M, Rutten F, Brenna A, et. al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 1993; 4 (3): 173-86
14. Raiffa H. Decision analysis: introductory lectures on choices under uncertainty. New York: McGraw Hill, 1968
15. Mansfield E. Statistics for business and economics. New York: W. W. Norton, 1987: 625-95
16. Clemens K, Garrison LP, Jones A. Strategic use of pharmacoeconomic research in early drug development and global pricing. Pharmacoeconomics 1993; 4 (5): 315-22
17. Schulpher MS, Drummond MF, Buxton MJ. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2(1): 26-30
18. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1987
19. Smith TJ, Hilner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995; 13 (9): 2166-73
20. Sharples LD, Briggs A, Caine N. A model for analyzing the cost of main clinical events after cardiac transplantation. Transplantation 1996; 6(5): 615-21
21. Spilker B. Multinational pharmaceutical companies: principles and practices. 2nd ed. New York: Raven Press, 1994: 567-83
22. Recombinant Capital. Index of life science agreements. San Francisco, CA: 1996
23. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995; 58 (1): 1-14
24. Grabowski H. Health reform and pharmaceutical innovation. Washington, DC: The AEI Press, 1994: 17-8
25. Moore SD, Revzin P. Success of Ciba-Sandoz merger will be tested in the lab. Wall Street Journal, 30 July 1996: B4
26. Pharmaceutical industry overview report: a fistful of dollars. New York: Bear Sterns & Co., Inc., 26 Aug 1996: 23
27. Drummond MF, Davies L. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561-73
28. Rittenhouse BE, O'Brien BJ. Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996: 1215-23
29. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc Sci Med 1997. In press
30. Sloan F, editor. Valuing health care: costs, benefits and effectiveness of pharmaceuticals and other medical technologies. Cambridge: Cambridge University Press, 1995
31. Spilker B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Raven Publishers, Part XI: 1077-228